. Author manuscript; available in PMC: 2009 Feb 1.

Published in final edited form as: Drug Discov Today. 2008 Feb 1;13(3-4):124–134. doi: 10.1016/j.drudis.2007.12.005

Table 2.

Current Clinical Trials: PDT as an Adjuvant to Other Therapeutic Agents

Therapeutic Combination	Comparative Trial	Application
Visudyne® / Lucentis (LUV Trial)	Combination therapy with intravitreal Lucentis and verteporfin PDT versus Intravitreal Lucentis alone	AMD/ CNV (Phase IV)
TAC-PF / Avastin® (VERTACL)	Triple therapy using intravitreal Avastin®, half fluence verteporfin PDT, and intravitreal triamcinolone acetonide-preservative free (TAC-PF) versus Intravitreal Avastin alone	AMD/CNV (Phase II)
Visudyne® / Avastin®	Visudyne PDT (low or very low fluence rate) combined with intravitreal injections Avastin versus Intravitreal Avastin alone	AMD/ CNV (Phase II)
Vatalanib / Visudyne®	Oral Vatalanib (VEGF-receptor tyrosine kinase inhibitor) with Visudyne® PDT versus Oral Vatalanib alone	AMD/ CNV (Phase II)
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone (RADICAL)	Reduced-fluence Visudyne followed by intravitreal Lucentis (within 2 h) or two regimens of reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy (within 2 h) versus Intravitreal Lucentis	AMD/ CNV (Phase II)